S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
Sell every Stock except ONE (Ad)
UK travelers face hours-long waits for ferries to France
'War of the states': EV, chip makers lavished with subsidies
JP Morgan analyst: Oil to hit $380 per barrel (Ad)
Gas prices increase in NJ, around nation amid higher demand
Lanterns and crescents: more retailers court Ramadan buyers
What’s At Stake In April is Shocking (Ad)pixel
Shipbuilder Austal executives accused of inflating earnings
No more room for vroom? Paris votes on banishing e-scooters
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
Sell every Stock except ONE (Ad)
UK travelers face hours-long waits for ferries to France
'War of the states': EV, chip makers lavished with subsidies
JP Morgan analyst: Oil to hit $380 per barrel (Ad)
Gas prices increase in NJ, around nation amid higher demand
Lanterns and crescents: more retailers court Ramadan buyers
What’s At Stake In April is Shocking (Ad)pixel
Shipbuilder Austal executives accused of inflating earnings
No more room for vroom? Paris votes on banishing e-scooters
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
Sell every Stock except ONE (Ad)
UK travelers face hours-long waits for ferries to France
'War of the states': EV, chip makers lavished with subsidies
JP Morgan analyst: Oil to hit $380 per barrel (Ad)
Gas prices increase in NJ, around nation amid higher demand
Lanterns and crescents: more retailers court Ramadan buyers
What’s At Stake In April is Shocking (Ad)pixel
Shipbuilder Austal executives accused of inflating earnings
No more room for vroom? Paris votes on banishing e-scooters
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
Sell every Stock except ONE (Ad)
UK travelers face hours-long waits for ferries to France
'War of the states': EV, chip makers lavished with subsidies
JP Morgan analyst: Oil to hit $380 per barrel (Ad)
Gas prices increase in NJ, around nation amid higher demand
Lanterns and crescents: more retailers court Ramadan buyers
What’s At Stake In April is Shocking (Ad)pixel
Shipbuilder Austal executives accused of inflating earnings
No more room for vroom? Paris votes on banishing e-scooters
NASDAQ:AURA

Aura Biosciences - AURA Stock Forecast, Price & News

$9.28
+0.40 (+4.50%)
(As of 03/31/2023 12:00 AM ET)
Add
Compare
Today's Range
$8.89
$9.40
50-Day Range
$8.88
$12.11
52-Week Range
$8.63
$24.83
Volume
126,085 shs
Average Volume
178,807 shs
Market Capitalization
$350.78 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$25.00

Aura Biosciences MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
169.4% Upside
$25.00 Price Target
Short Interest
Bearish
4.83% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
$3,960 Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.17) to ($2.76) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.62 out of 5 stars

Medical Sector

821st out of 996 stocks

Biological Products, Except Diagnostic Industry

140th out of 165 stocks


AURA stock logo

About Aura Biosciences (NASDAQ:AURA) Stock

Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develops AU-011 in additional ocular oncology indications, including choroidal metastases. The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.

Receive AURA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aura Biosciences and its competitors with MarketBeat's FREE daily newsletter.

AURA Stock News Headlines

"Prepare for Five Years of Famine"
Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecast.
JMP Securities Reaffirms Their Buy Rating on Aura Biosciences Inc (AURA)
"Prepare for Five Years of Famine"
Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecast.
Why Shares of Aura Biosciences Jumped This Week
See More Headlines
Receive AURA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aura Biosciences and its competitors with MarketBeat's FREE daily newsletter.

AURA Company Calendar

Last Earnings
3/15/2023
Today
4/01/2023
Next Earnings (Estimated)
5/11/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AURA
Fax
N/A
Employees
52
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$25.00
High Stock Price Forecast
$25.00
Low Stock Price Forecast
$25.00
Forecasted Upside/Downside
+169.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-58,760,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$6.67 per share

Miscellaneous

Free Float
35,910,000
Market Cap
$350.78 million
Optionable
Not Optionable
Beta
0.12

Key Executives

  • Dr. Elisabet de los Pinos Ph.D. (Age 49)
    Founder, CEO, Pres & Director
    Comp: $676.62k
  • Ms. Julie B. Feder (Age 53)
    CFO, Sec. & Treasurer
    Comp: $505.45k
  • Dr. Cadmus Collins Rich CPE (Age 58)
    M.B.A., M.D., MBA, Chief Medical Officer and Head of R&D
    Comp: $564.22k
  • Dr. Mark A. De Rosch Ph.D. (Age 59)
    Chief Operating Officer
  • Mr. Paulo Carvalho
    VP of Technical Operations
  • Mr. Joseph Lyons
    VP of HR
  • Ms. Michele Keough M.B.A.
    Sr. VP of Project Management and Device Supply Chain













AURA Stock - Frequently Asked Questions

Should I buy or sell Aura Biosciences stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aura Biosciences in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" AURA shares.
View AURA analyst ratings
or view top-rated stocks.

What is Aura Biosciences' stock price forecast for 2023?

1 brokerages have issued 12-month price objectives for Aura Biosciences' shares. Their AURA share price forecasts range from $25.00 to $25.00. On average, they expect the company's stock price to reach $25.00 in the next twelve months. This suggests a possible upside of 169.4% from the stock's current price.
View analysts price targets for AURA
or view top-rated stocks among Wall Street analysts.

How have AURA shares performed in 2023?

Aura Biosciences' stock was trading at $10.50 at the beginning of 2023. Since then, AURA shares have decreased by 11.6% and is now trading at $9.28.
View the best growth stocks for 2023 here
.

Are investors shorting Aura Biosciences?

Aura Biosciences saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 1,250,000 shares, an increase of 30.2% from the February 28th total of 960,000 shares. Based on an average daily trading volume, of 115,300 shares, the days-to-cover ratio is currently 10.8 days. Approximately 4.8% of the shares of the company are short sold.
View Aura Biosciences' Short Interest
.

When is Aura Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 11th 2023.
View our AURA earnings forecast
.

How were Aura Biosciences' earnings last quarter?

Aura Biosciences, Inc. (NASDAQ:AURA) announced its earnings results on Wednesday, March, 15th. The company reported ($0.52) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.58) by $0.06.

What ETFs hold Aura Biosciences' stock?

ETFs with the largest weight of Aura Biosciences (NASDAQ:AURA) stock in their portfolio include AltShares Event-Driven ET (EVNT).ALPS Medical Breakthroughs ETF (SBIO).

When did Aura Biosciences IPO?

(AURA) raised $81 million in an initial public offering (IPO) on Friday, October 29th 2021. The company issued 5,400,000 shares at a price of $14.00-$16.00 per share.

What is Aura Biosciences' stock symbol?

Aura Biosciences trades on the NASDAQ under the ticker symbol "AURA."

How do I buy shares of Aura Biosciences?

Shares of AURA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aura Biosciences' stock price today?

One share of AURA stock can currently be purchased for approximately $9.28.

How much money does Aura Biosciences make?

Aura Biosciences (NASDAQ:AURA) has a market capitalization of $350.78 million. The company earns $-58,760,000.00 in net income (profit) each year or ($1.96) on an earnings per share basis.

How can I contact Aura Biosciences?

The official website for the company is www.aurabiosciences.com. The company can be reached via phone at 617-500-8864 or via email at aura@argotpartners.com.

This page (NASDAQ:AURA) was last updated on 4/2/2023 by MarketBeat.com Staff